Avalon Globocare To Acquire Leading Laboratory With 2021 Unaudited Revenue Of Over $25 Mln
T-Reuters
08 Nov 2022
Avalon Globocare Corp :Avalon Globocare Signs Definitive Agreement For Transformational Acquisition Of Leading Laboratory With 2021 Unaudited Revenue In Excess Of $25 Million.Company To Begin Trading Under New Symbol "Albt" On November 10, 2022.Total Consideration For Acquisition Will Be $31 Million.Avalon Globocare - Deal Cash Portion To Be Financed With Private Placement Of $15 Million Of Preferred Stock, Convertible At A Floor Of $1.00 Per Share.Shares Of Co'S Common Stock Will Begin Trading Under New Ticker Symbol "Albt" On Nasdaq Capital Market On Thursday, Nov 10.Sarah Cox, Co-Founder And Ceo Of Laboratory Services, Will Become Chief Operating Officer Of Company.Has Signed A Definitive Acquisition Agreement To Acquire A 60% Interest In Laboratory Services Mso, Llc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.